AI Article Synopsis
- The study investigates cardiovascular disease mortality in Iran, focusing on 28-day mortality rates after Acute Myocardial Infarction (AMI) from 2000 to 2017.
- It uses data from a hospital registry in Isfahan and employs Cox regression analyses to determine risk factors related to age, gender, and living region.
- Findings show that older age and male gender increase the risk of AMI mortality, while younger age and urban living are protective factors, with a notable decline in mortality rates observed from 2006 to 2017.
Article Abstract
Background: The study explores the enduring challenges of cardiovascular disease mortality, emphasizing myocardial infarction rates as a proxy for cardiovascular disease in Iran. It analyzes the 28-day mortality trends after Acute Myocardial Infarction (AMI) from 2000 to 2017.
Methods: This retrospective cohort study is based on data from a multi-centric hospital-based registry in Isfahan. Univariate and multivariate frailty Cox regression analyses were performed to identify Hazard Ratios (HRs) for the 28-day mortality rate of AMI based on age, gender, and living region.
Results: The study enrolled 121,284 patients with an average age of 62.00±12.82 years. Older age than 65 years was found to be associated with an increased risk of AMI (HR: 3.2, 95% CI: 2.7-3.8 from 2000 to 2002 and HR: 4.6, 95% CI: 3.7-5.7 for 2015-2017). There was also an association between living in the urban region and a decreased risk of AMI from 2000 to 2005 (HR: 0.64, 95% CI: 0.46-0.90), from 2000 to 2002 (HR: 0.55, 95% CI: 0.43-0.71 for 2003-2005). Results showed that the trend of change in 28-day mortality declined more significantly from 2006 to 2017 compared to 2000-2002. Younger age (61.76±12.69 vs 71.12±11.73), female gender (HR:0.77, 95%CI: 0.67,0.89), and living in urban regions (HR: 0.69, 95%CI: (0.52,0.94) were the protective factors for the 28-days mortality rate of AMI.
Conclusion: It can be concluded that 28-day mortality had a descending trend from 2006 to 2017. Older age, male gender, and living in a rural region were the risk factors that affected the 28-day mortality rate of AMI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651309 | PMC |
| http://dx.doi.org/10.48305/arya.2023.42291.2929 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of the geriatric nutritional risk index with poor outcomes in patients with coronary revascularization: a cohort study.
Front Cardiovasc Med
December 2024
Cardiovascular Department, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Poor nutritional status may affect outcomes after coronary revascularization, but the association between nutritional status and outcomes in patients undergoing coronary revascularization has not been fully evaluated. This study was based on the MIMIC-IV database to analyze the impact of baseline nutritional status on poor outcomes in patients with coronary revascularization.
Methods: Patients with coronary revascularization were screened from the MIMIC-IV database.
Impact of early initiation of renal replacement therapy in patients on venoarterial ECMO using target trial emulation with Japanese nationwide data.
Sci Rep
January 2025
Department of Intensive Care Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
While renal replacement therapy (RRT) allows for precise fluid management as well as addressing electrolyte imbalances and the removal of other necessary compounds, its early initiation has not shown benefit in the general critically ill population. Moreover, the effects of early RRT initiation specifically in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO) also remain unclear. This retrospective study investigated adult patients who underwent VA-ECMO between April 2018 and March 2022 and used the clone-censor-weight method to emulate a hypothetical target trial and compare two groups: patients who initiated RRT within 2 days of VA-ECMO initiation (Early) and those who did not (Late).
View Article and Find Full Text PDFRepurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease.
Gut Liver
January 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Alcohol-related liver disease (ALD) is a serious global health concern, characterized by liver inflammation and progressive fibrosis. There are no Food and Drug Administration-approved drugs, thus effective treatments are needed. Severe alcoholic hepatitis (AH) is the most severe manifestation of ALD, with a 28-day mortality rate ranging from 20% to 50%.
View Article and Find Full Text PDFBackground: Cirrhosis is the end stage of chronic liver disease. Cirrhosis causes portal hypertension, which, in turn, can lead to acute on chronic liver failure (ACLF), which is defined as acute decompensation combined with failure of the liver, coagulation system, kidneys, lungs, and/or circulatory system, or hepatic encephalopathy.
Methods: This review is based on a selective literature search for international publications in the NCBI database using the keywords "liver cirrhosis" and "ACLF.
The Role of Immune Semaphorins in Sepsis-A Prospective Cohort Study.
Microorganisms
December 2024
Department for Infectious Diseases, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
In sepsis, a balanced pro-inflammatory and anti-inflammatory response results in the bacterial clearance and resolution of inflammation, promoting clinical recovery and survival. Semaphorins, a large family of secreted and membrane-bound glycoproteins, are newly recognized biomarkers and therapeutic targets in immunological and neoplastic disorders. Although semaphorins might also be a crucial part of host defense responses to infection, their role in sepsis is yet to be determined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!